Background: Sertoli Leydig cell tumors  SLCT  of the ovary are rare, and usually present as progressive virilization in omen in their second to third decade of life. Less than 10 percent of patients are reportedly older than age 50. Methods: A retrospective revie as performed of all cases of histologically proven ovarian SLCT diagnosed at a tertiary care institution beteen 1990 -2014. Results: Of the 16 patients diagnosed ith SCLT over a 24-year period, nine patients  56 percent  ere postmenopausal at the time of diagnosis ith a median age of 52.5 years  IQR = 39.7 years . These 9 patients had a median interval of 14.7 years  IQR = 15  since the onset of menopause. Hyperandrogenism as a presenting feature in only 5 of 16  31 percent  [median age of 49  IQR = 26.5 ] hereas postmenopausal bleeding as noted in 2 of 16  12 percent . Only 3 of the patients ith hyperandrogenism had preoperative hormonal assays confirming elevated total testosterone. Nine patients  56 percent , presented ith vague symptoms of abdominal pain or bloating and ere noted to have pelvic masses that ere diagnosed as SLCT at the time of surgical removal. At diagnosis, tumor grade varied from ell-differentiated to poorly-differentiated lesions. Nine lesions  56 percent  ere of intermediate differentiation, and 8 patients  15 percent  received adjuvant chemotherapy. The decision to give adjuvant treatment as made for cases of higher than stage IA cancer, cases here concurrent tumors ere identified on the surgical specimen, or in cases of poor tumor differentiation. Disease free survival over a median folloup of 31.5 months  IQR = 73.5 months  as 100 percent. At the time of this study, all patients are alive ith no recurrences ith the exception of one ho died from unrelated causes. Conclusions: Our patient population ith SLCT as noticeably older than hat has been described in literature, ith greater than 50 percent being postmenopausal. To the best of our knoledge, this is the largest case series of postmenopausal patients ith SLCT. Features of androgen excess and abnormal bleeding ere evident in only a small sub-group. While the definitive management approach to SLCT remains controversial and varied, prognosis folloing definitive surgery and risk of recurrence are reassuring.,J Clin Oncol 34, 2016  suppl; abstr e17052 ,Publication Only Gynecologic Cancer